Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Ironwood Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091987
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income (loss) | $92,064 | $(13,787) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Depreciation and amortization | 900 | 946 |
| Loss on disposal of property and equipment | — | 85 |
| Share-based compensation expense | 6,889 | 9,815 |
| Non-cash interest expense | 808 | 832 |
| Non-cash lease expense | 897 | 827 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ironwood Pharmaceuticals's D&A?
- Ironwood Pharmaceuticals (IRWD) reported D&A of $457K in Q2 2026.
- How has Ironwood Pharmaceuticals's D&A changed year-over-year?
- Ironwood Pharmaceuticals's D&A decreased by 2.1% year-over-year, from $467K to $457K.
- What is the long-term trend for Ironwood Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), Ironwood Pharmaceuticals's D&A has grown at a 5.4% compound annual growth rate (CAGR), from $1.52M to $1.88M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Ironwood Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude